Drugs / Ad26.Mos4.HIV
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06205056 | Jan 2024 → Dec 2025 overdue | HIV infectious disease | U.S. Army Medical Research and Development Command | Recruiting | No outcome recorded |
| Phase 1 | NCT05769569 | Sep 2023 → Jul 2025 | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT03307915 | Mar 2018 → Nov 2021 | HIV infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04983030 | Apr 2022 → Feb 2026 | AIDS, acquired immunodeficiency | Boris Juelg, MD PhD | Completed | No outcome recorded |
| Phase 1/2 | NCT02935686 | Mar 2017 → Nov 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02788045 | Jul 2016 → Apr 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03060629 | Nov 2017 → Feb 2022 | — | Janssen Vaccines & Prevention B.V. | Terminated | Missed primary |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT03964415 | Oct 2019 → Aug 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-01-18 | Janssen Research & Development, LLC | Results Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial jnj.com ↗
The Mosaico DSMB analysis, based on the data available to date, indicated that the regimen does not protect against HIV and the study is not expected to meet its primary endpoint. |
| 2021-08-31 | Janssen Research & Development, LLC | Results Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗
Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. |
| 2021-08-31 | Janssen Research & Development, LLC | Results Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗
Data showed the investigational HIV vaccine regimen did not provide sufficient protection against HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. |
| 2019-07-23 | Janssen Research & Development, LLC | Results Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen jnj.com ↗
In the study, both regimens induced high immune responses against a broad range of HIV-1 subtypes. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-01-18 | Janssen Research & Development, LLC | Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial jnj.com ↗ |
| 2021-08-31 | Janssen Research & Development, LLC | Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗ |
| 2021-08-31 | Janssen Research & Development, LLC | Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa jnj.com ↗ |
| 2019-07-23 | Janssen Research & Development, LLC | Johnson & Johnson Announces New Clinical Data on Mosaic-based HIV Preventive Vaccine Regimen jnj.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.Mos4.HIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205056 ↗ |
| Modality | Vaccine | “Ad26 vectored vaccine” NCT02788045 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT02788045 ↗ |